Table 4.
Standardized mortality ratios among 64,836 HIV-infected patients initiating combination antiretroviral therapy stratified by patient characteristics, the China National Free Antiretroviral Treatment Program 2003 – 2009
| Characteristic | 2003–2004 | 2005–2007 | 2008–2009 |
|---|---|---|---|
| Age | |||
| 18–29 | N/A* | 114.9 (102.0 – 129.5) | 70.8 (63.5 – 79.0) |
| 30–44 | 54.1 (49.2 – 59.4) | 37.8 (36.2 – 39.4) | 31.6 (30.4 – 33.0) |
| ≥45 | 16.8 (14.9 – 18.9) | 13.4 (12.7 – 14.1) | 9.1 (8.6 – 9.6) |
| Gender | |||
| Men | 30.9 (28.1 – 33.9) | 21.9 (21.0 – 22.8) | 15.6 (15.0 – 16.2) |
| Women | 30.7 (27.4 – 34.3) | 24.9 (23.7 – 26.2) | 20.7 (19.6 – 21.8) |
| HIV exposure | |||
| Blood transfusion/former plasma donation | 30.7 (28.6 – 33.1) | 22.5 (21.7 – 23.3) | 16.2 (15.5 – 16.9) |
| Intravenous drug use | N/A* | 47.6 (41.5 – 54.5) | 53.9 (50.1 – 57.9) |
| Sexual transmission | 28.2 (17.8 – 44.7) | 22.6 (20.8 – 24.5) | 13.3 (12.5 – 14.1) |
| Area of residence | |||
| Rural | 30.6 (28.5 – 33.0) | 22.5 (21.7 – 23.3) | 16.9 (16.3 – 17.5) |
| Urban | 37.1 (24.4 – 56.3) | 26.4 (24.2 – 28.7) | 17.4 (16.4 – 18.6) |
| Health care setting | |||
| General hospital | N/A* | 29.0 (26.3 – 31.9) | 19.8 (18.5 – 20.9) |
| Infectious diseases hospital | N/A* | 16.4 (14.1 – 19.1) | 9.0 (7.9 – 10.2) |
| Centers for diseases control clinic | 56.7 (44.9 – 71.7) | 28.8 (26.4 – 31.4) | 20.9 (19.5 – 22.4) |
| Health care under township level/prison hospital | 29.3 (27.1 – 31.7) | 21.9 (21.1 – 22.7) | 16.3 (15.6 – 17.1) |
| CD4 cell count (cells/μL) | |||
| 0–49 | 103.6 (86.2 – 124.5) | 61.3 (57.8 – 64.9) | 32.2 (30.5 – 34.0) |
| 50–199 | 25.0 (20.8 – 30.2) | 20.0 (18.8 – 21.2) | 15.4 (14.6 – 16.3) |
| 200–349 | 4.8 (3.1 – 7.2) | 9.4 (8.5 – 10.4) | 9.7 (8.8 – 10.5) |
| ≥350 | 7.1 (5.0 – 10.2) | 5.6 (4.8 – 6.6) | 6.7 (5.7 – 7.9) |
| Number of baseline symptom | |||
| 0 | 32.0 (25.5 – 40.2) | 11.9 (10.6 – 13.4) | 10.2 (9.4 – 11.1) |
| 1 | 20.6 (15.5 – 27.3) | 17.8 (15.9 – 19.9) | 15.1 (13.8 – 16.6) |
| 2–3 | 21.0 (18.0 – 24.6) | 21.8 (20.5 – 23.2) | 17.1 (16.1 – 18.2) |
| ≥4 | 38.8 (35.4 – 42.6) | 28.0 (26.8 – 29.2) | 21.5 (20.6 – 22.5) |
| Initiation regimen† | |||
| NVP+3TC+AZT | N/A* | 24.8 (21.7 – 28.3) | 17.4 (16.2 – 18.8) |
| NVP+3TC+D4T | 3.4 (1.1 – 10.5) | 28.3 (26.7 – 30.0) | 16.5 (15.7 – 17.4) |
| NVP+DDI+AZT | 35.7 (32.9 – 38.7) | 22.1 (21.2 – 23.2) | 16.4 (15.5 – 17.4) |
| NVP+DDI+D4T | 22.7 (18.7 – 27.4) | 16.6 (14.9 – 18.6) | 12.1 (10.5 – 14.0) |
| EFV+3TC+AZT | N/A* | 12.2 (8.8 – 16.9) | 20.5 (17.9 – 23.5) |
| EFV+3TC+D4T | N/A* | 25.6 (21.4 – 30.6) | 21.5 (19.3 – 23.9) |
| Other regimens | 18.9 (12.1 – 29.6) | 19.0 (15.4 – 23.3) | 23.8 (20.1 – 28.3) |
*
N/A: Standardized mortality ratios were not estimated within strata with expected deaths fewer than 0.5 patients.
†
NVP= nevirapine; 3TC=lamivudine; AZT= zidovudine; d4T=stavudine; DDI=didanosine; EFV=efavirenz.